Treatment schema: a pooled analysis of 2 phase 2 clinical trials and a retrospectively identified nontrial cohort. In each cohort, patients received 3 cycles of RB and 3 cycles of RC. In the DFCI trial, the starting dose of cytarabine was reduced from 3 g/m² to 2 g/m² for patients >60 years with a further dose reduction to 1.5 g/m² for patients >60 years with either renal dysfunction (creatinine, 1.3-2.0) or preexisting neurotoxicity or 1.0 g/m² for patients >60 years with both renal dysfunction and preexisting neurotoxicity. In the WUSTL trial, the starting dose of cytarabine was reduced to 2 g/m² for patients >60 years and/or with renal dysfunction (estimated glomerular filtration rate, 40-59). *The starting cytarabine dose was chosen by the treating physician for patients treated in the nontrial cohort. BID, twice a day.